Henry Hebel has over twenty years of experience in biologics development, production and regulatory compliance in major global markets. Mr. Hebel was previously the Vice President of Drug Development for Terapio were he successfully developed a radiation countermeasure product by solving previously insurmountable hurdles in drug product purity and concentration for a large complex product, allowing the organization to progress to preclinical studies and entry into critical government countermeasure development programs. Additionally, Mr. Hebel was Chief Operating Officer of VGXI Inc. where he led the virtual company to operational in-house cGMP production in support of FDA and USDA clinical submissions within two years. VGXI continued to expand operations under Mr. Hebel’s guidance and successfully obtained the world’s first commercial gene therapy medical device combination product approval. Prior to VGXI, Mr. Hebel served as Key Account Manager at Qiagen, Inc. for the strategic joint venture known as the “pAlliance”. Mr. Hebel worked on the pAlliance team that launched the venture to provide CMO capabilities to the then emerging biotech market and was responsible for sales, marketing and project management activities. Mr. Hebel also worked as the Senior Manager of Bioprocessing for GeneMedicine Inc. The Bioprocessing team at GeneMedicine designed, built and operated a cGMP manufacturing facility using novel manufacturing methods and was responsible for the production of human clinical materials through Phase II clinical trials. Mr. Hebel has additional antibody product development and manufacturing experience at Tanox Biosystems, Inc. Mr. Hebel holds a Bachelor of Science degree in Zoology and a Masters of Business Administration degree from Texas A&M University.
![]()
